相关实验视频

Updated: May 6, 2026

A Unified Methodological Framework for Vestibular Schwannoma Research

A Unified Methodological Framework for Vestibular Schwannoma Research

Published on: June 20, 2017

临床分析了19例缺乏差异化的冠状瘤病例,这些病例使用多种不同的治疗方式治疗

Wei Wang¹, Yajie Cui², Renkun Nie³

¹Department of Comprehensive Treatment, Hebei Yizhou Cancer Hospital, Zhuozhou, China.

Discover oncology

|October 8, 2025

概括

这项研究分析了19例差差分化的心肌瘤 (PDCs),发现虽然手术和辅助疗法等治疗可以改善结果,但年轻的年龄和断层位置与差差分化有关. 需要进一步的研究来确认预后因素和免疫疗法的有效性.

科学领域:

在瘤学瘤学.
手术病理学手术病理学
辐射疗法辐射疗法

背景情况:

迫切需要改善差分化胆瘤 (PDCs) 的诊断和治疗策略.
临床病例分析对于理解具有挑战性的冠状瘤亚型至关重要.

研究的目的:

分析患有差差分化的冠状瘤的患者的临床数据.
确定潜在的预后因素,并评估治疗结果.

主要方法:

对19名病理确诊的,差异化不良的冠状腺瘤患者的回顾性审查.
手术切除之后进行各种辅助疗法,包括质子辐射,化疗,向疗法和免疫疗法.
使用多元物流回归,顺序物流回归,COX比例危险模型和卡普兰-梅尔生存分析的统计分析.

主要成果:

确定了12种PDC,4种非分化冠状瘤 (DDC) 和3种低分化冠状瘤 (LDC).
年龄较小与差异化较高相关 (P<0.05).
片状冠状瘤表现出最差的分化和最高的恶性瘤 (P<0.001).
在这个队列中,没有在性别,差异化,位置,治疗或手术切除比率方面确定任何独立的预后因素.

结论:

手术切除结合辅助化疗,放射治疗和向治疗可能为PDCs提供一些预后益处.
免疫疗法在PDCs中的有效性需要进一步研究.
更大的人口研究是必要的,以验证潜在的预后因素为chordoma结果.

关键词:

案例分析案例分析差异化不良的冠状腺瘤治疗方式治疗方式

更多相关视频

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Published on: June 9, 2023

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...